超声、球囊导管与肌电图联合引导下环咽肌注射肉毒毒素治疗卒中后环咽肌功能障碍的随机双盲安慰剂对照试验方案
本研究为单中心随机双盲安慰剂对照优效性试验,计划纳入44例卒中后环咽肌功能障碍患者,1:1随机接受环咽肌注射肉毒毒素或安慰剂,采用超声、球囊导管与肌电图联合引导精准定位,主要结局为功能性经口摄食量表评分。
要点
- 环咽肌注射肉毒毒素治疗神经源性环咽肌功能障碍的成功率报道为43%至100%(均值76%),但缺乏高质量随机对照证据。
- 本研究采用超声、球囊导管和肌电图联合引导(BECURE)精准定位环咽肌进行注射。
- 主要结局为功能性经口摄食量表(FOIS)评分,次要结局包括上食管括约肌压力参数及吞咽安全性指标。
核心结论
- 本研究旨在明确超声、球囊导管和肌电图联合引导下环咽肌注射肉毒毒素治疗卒中后环咽肌功能障碍的有效性和安全性。
研究设计与样本
- BECURE为单中心、随机、安慰剂对照、双盲、优效性临床试验,计划样本量44例,按1:1随机分配至肉毒毒素组或安慰剂组。
- 随机序列1至44由Statistical Package for Social Sciences生成,研究分两阶段:第一阶段注射肉毒毒素或安慰剂,第二阶段安慰剂组及第一阶段肉毒毒素无应答者接受肉毒毒素注射。
- 试验注册于中国临床试验注册中心(ChiCTR1900025562),注册日期2019年9月1日。
关键数值与推荐
- 主要结局为功能性经口摄食量表(FOIS)评分。
- 次要结局包括上食管括约肌残余压、静息压、松弛持续时间、鼻咽和喉咽峰值压力、上食管括约肌开放、咽收缩比、会厌谷或梨状窦食团残留及渗漏和误吸。
- 原文提及环咽肌注射肉毒毒素对部分吞咽困难患者有效且安全,成功率介于43%至100%(均值76%)。
临床怎么用
- 若试验证实有效,超声、球囊导管和肌电图联合引导下环咽肌注射肉毒毒素可作为卒中后环咽肌功能障碍的精准治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cricopharyngeal dysfunction (CPD) occurs in various neurological disorders, especially stroke. The treatment approaches of CPD include swallowing training, cricopharyngeal dilation, botulinum toxin (BTX) injection, and cricopharyngeal myotomy. BTX injection into the cricopharyngeal muscle is effective and safe for some patients with dysphagia, with a success rate between 43 and 100% (mean = 76%). However, well-designed randomized controlled clinical trials are needed to verify its efficacy and safety for the treatment of CPD. The objective of this study is to explore the efficacy and safety of BTX for neurogenic cricopharyngeal achalasia, when administering an injection into the cricopharyngeal muscle guided by a novel precise positioning method, that combines ultrasound, catheter balloon, and electromyography (BECURE). METHODS: BECURE is a single-center randomized, placebo controlled, double-blinded, superiority clinical trial. To detect a significant difference between the 2 groups, a sample size of 44 patients is estimated. The intervention is BTX versus placebo, with 1:1 randomization. The randomization sequence from 1 to 44 was generated using the Statistical Package for Social Sciences. The study is divided into two phases. In the first phase, patients will be injected with BTX or the placebo. In the second phase, patients who received a placebo injection and those who did not respond to the first BTX injection will receive an injection of BTX. The primary outcome is the score of the Functional Oral Intake Scale (FOIS). The secondary outcomes are as follows: upper esophageal sphincter (UES) residual pressure, UES resting pressure, duration of UES relaxation, velopharyngeal and laryngopharyngeal peak pressure, UES opening, pharyngeal construction ratio, residue of bolus in the epiglottis valley or piriform sinus, and penetration and aspiration. DISCUSSION: Dysphagia is a common complication of stroke. There is lack of high-quality evidence for the efficacy of BTX in treating neurogenic CPD. This study will clarify whether BTX injection into the cricopharyngeal muscle can be effective and safe for patients with stroke and CPD. TRIAL REGISTRATION: Chinese Clinical Trial Register ( ChiCTR1900025562 ). Registered on September 1, 2019.
引用
- Xie M, Dou Z, Wan G, et al. Design and implementation of botulinum toxin on cricopharyngeal dysfunction guided by a combination of catheter balloon, ultrasound, and electromyography (BECURE) in patients with stroke: study protocol for a randomized, double-blinded, placebo-controlled trial. Trials. 2021. PMID: 33789722. doi:10.1186/s13063-021-05195-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。